Forest buys out Janssen's Bystolic royalties for $357 million
This article was originally published in Scrip
Executive Summary
Forest Laboratories has bought for $357 million the US and Canadian intellectual property relating to Bystolic (nebivolol), the only branded beta blocker in the US market. The deal means that Janssen, which developed the drug, will not receive any future royalties on the drug.